Intellia Therapeutics, Inc. business relationships

Companies named in Intellia Therapeutics, Inc.’s 10-K filed 2026-02-26, and public companies whose annual reports name Intellia Therapeutics, Inc.. Each link shows the sentence it came from. Scores are Engagemii’s AI visibility scores.

Open on the map Full AI visibility profile

AEO visibility: 5.4 / 10
AI naming: 72 / 100
Agent readiness: 0 / 100
AI adoption: 0 / 100

Named in Intellia Therapeutics, Inc.’s annual report 7

Blackstone Inc. (BX)Partner7.7
“AvenCell Therapeutics, Inc. ("AvenCell") was formed in July 2021 as a joint venture between us, Cellex Cell Professionals GmbH ("Cellex") and funds managed by Blackstone Life Sciences Advisors L.L.C. ("BXLS").” SEC filing
REGENERON PHARMACEUTICALS, INC. (REGN)Partner7.7
“As of December 31, 2025, the Company's accounts receivable and contract liabilities were related to its collaboration with Regeneron.” SEC filing
REGENERON PHARMACEUTICALS, INC. (REGN)Supplier7.7
“Under this agreement, we also may access the Regeneron Genetics Center and proprietary mouse models to be provided by Regeneron for a limited number of our liver programs.” SEC filing
CRISPR Therapeutics AG (CRSP)Licensor5.5
“...and defense of this intellectual property in its license agreement with Caribou and, pursuant to an Invention Management Agreement, shares these responsibilities with CRISPR Therapeutics AG and, under certain circumstances, ERS Genomics, Ltd., as the designated managers of the intellectual property.” SEC filing
ERS Genomics, Ltd.Licensor4.7
“...and defense of this intellectual property in its license agreement with Caribou and, pursuant to an Invention Management Agreement, shares these responsibilities with CRISPR Therapeutics AG and, under certain circumstances, ERS Genomics, Ltd., as the designated managers of the intellectual property.” SEC filing
ReCode Therapeutics, Inc.Partner4.6
“As of December 31, 2024, the Company's accounts receivable were related to its collaborations with Regeneron, SparingVision SAS ("SparingVision"), AvenCell Therapeutics, Inc. ("AvenCell") and ReCode Therapeutics, Inc. ("ReCode") .” SEC filing
Caribou Biosciences, Inc. (CRBU)Licensor4.2
“For example, through a license agreement between Caribou Biosciences, Inc. and us (the "Caribou License"), we sublicense the rights of the Regents of the University of California and the University of Vienna (collectively, "UC/Vienna") to a worldwide patent portfolio that covers methods of use and c...” SEC filing

Companies whose annual reports name Intellia Therapeutics, Inc. 3

REGENERON PHARMACEUTICALS, INC. (REGN)names it as partner7.7
“We and Intellia Therapeutics, Inc. are parties to a license and collaboration agreement to advance CRISPR/Cas9 gene-editing technology for in vivo therapeutic development, including therapies focused on neurological and muscular diseases.” SEC filing
Kyverna Therapeutics, Inc. (KYTX)names it as partner4.7
“In December 2021, the Company entered into a License and Collaboration Agreement (the "Intellia Agreement") with Intellia Therapeutics, Inc. ("Intellia") to research and develop an allogeneic CD19-directed CAR cell therapy product (the "CRISPR Product"), suitable for validation through pre-clinical...” SEC filing
Caribou Biosciences, Inc. (CRBU)names it as licensor4.2
“On July 16, 2014, we entered into a License Agreement (as amended, "Intellia License Agreement") with Intellia, LLC, to which Intellia Therapeutics, Inc. ("Intellia") is a successor in interest.” SEC filing

Links are read automatically from SEC annual reports (10-K, 20-F, 40-F). In a hand check of random links, about 8 in 10 were real business relationships, so every link carries its source sentence.